Page last updated: 2024-11-05

3-hydroxypyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Hydroxypyridine is a heterocyclic organic compound. It is a colorless solid, soluble in water and organic solvents. It is a versatile building block in organic synthesis, serving as an intermediate in the production of various pharmaceuticals, agrochemicals, and dyes. 3-hydroxypyridine exhibits biological activity as a potential antifungal agent, exhibiting inhibitory effects on the growth of certain fungi. Its mechanism of action is thought to involve interference with the biosynthesis of essential fungal metabolites. The compound is also known to possess antioxidant properties, which are attributed to its ability to scavenge free radicals. Furthermore, 3-hydroxypyridine has been investigated for its potential therapeutic effects in the treatment of neurological disorders and cancer. Research efforts are ongoing to understand the full spectrum of its biological activities and to develop novel applications in medicine and other fields.'

3-hydroxypyridine: RN given refeirs to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-pyridinol : A monohydroxypyridine that is pyridine in which the hydrogen at position 3 has been replaced by a hydroxy group. It has been detected as a thermal degradation product from the smoke of the burning leaves of Salvia divinorum, a Mexican psychoactive plant. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
SalviagenusA genus in the mint family (LAMIACEAE).[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]
Salvia divinorumspecies[no description available]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID7971
CHEMBL ID237847
CHEBI ID87440
MeSH IDM0080807

Synonyms (57)

Synonym
AC-907/25014060
m-hydroxypyridine
beta-hydroxypyridine
3-pyridyl alcohol
einecs 203-637-4
ai3-19237
nsc 18470
.beta.-hydroxypyridine
3-pyridinol
3-hydroxypyridine
nsc-18470
3-pyridol
nsc18470
109-00-2
3-oxopyridine
3-pyridone
inchi=1/c5h5no/c7-5-2-1-3-6-4-5/h1-4,7
pyridin-3-ol
3-hydroxypyridine, 98%
467D3257-37E0-4666-B266-CF679BC6CE5A
bdbm50225189
chebi:87440 ,
sr-1c8
CHEMBL237847 ,
H0331
STK802047
AKOS000119647
4kbe4p5b6s ,
unii-4kbe4p5b6s
BBL010946
BP-12457
FT-0615864
AM20050659
80618-81-1
3-hydoxypyridine
3-hydroxy-pyridine
pyridine-3-ol
3-hydroxylpyridine
DTXSID1051563
BS-3731
STR00285
W-108709
mfcd00006378
CS-W009147
F1995-0197
3-hydroxypyridine, vetec(tm) reagent grade, 99%
71a ,
3-oxidopyridinium
BCP26364
Q223089
D70736
3-oxypyridine
SB52272
EN300-20091
HY-Y1129
Z104476790
PD158448

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The toxic effects of GLAP and GA-pyridine were suppressed in the presence of anti-RAGE antibody or the soluble form of RAGE protein."( Receptor for advanced glycation end products (RAGE)-mediated cytotoxicity of 3-hydroxypyridinium derivatives.
Daikoh, T; Fujino, T; Hasegawa, T; Hayase, F; Kurachi, R; Miura, A; Murakami, Y; Usui, T; Watanabe, H, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monohydroxypyridineA hydroxypyridine carrying a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)767.36100.00011.753610.0000AID428564
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1339469Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID1403524Cytostatic activity against human T98G cells assessed as reduction in cell viability after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144New antiglioma zwitterionic pronucleotides with an FdUMP framework.
AID303044Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID1339468Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to contr2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID1127995Toxicity in Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID303043Cytotoxicity against human MIA PaCa2 cells after 4 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID1403521Cytostatic activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144New antiglioma zwitterionic pronucleotides with an FdUMP framework.
AID1127992Inhibition of NorA in fluoroquinolone-resistant Staphylococcus aureus 1199B assessed as potentiation of 4 ug/ml of ciprofloxacin MIC at 100 ug/ml after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID1127996Toxicity in fluoroquinolone-resistant Staphylococcus aureus 1199B expressing NorA after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID428564Inhibition of CYP3A42009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
AID1403528Cytostatic activity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144New antiglioma zwitterionic pronucleotides with an FdUMP framework.
AID1410758Reactivation of EMP-inhibited electric eel AChE assessed as enzyme reactivation by measuring residual activity at 0.4 mM at pH 8 after 1 hr using acetylthiocholine as substrate by Ellman's assay relative to control2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
Demonstration of In Vitro Resurrection of Aged Acetylcholinesterase after Exposure to Organophosphorus Chemical Nerve Agents.
AID1403525Cytostatic activity against human U118MG cells assessed as reduction in cell viability after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144New antiglioma zwitterionic pronucleotides with an FdUMP framework.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (116)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (29.31)18.7374
1990's17 (14.66)18.2507
2000's23 (19.83)29.6817
2010's37 (31.90)24.3611
2020's5 (4.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.34 (24.57)
Research Supply Index4.93 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index52.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (6.15%)5.53%
Reviews3 (2.31%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other119 (91.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]